CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals, the leading sirtuin therapeutics company, announced today that the company’s initial clinical candidate, SRT501, was found to be safe and well tolerated when administered orally in two Phase 1 clinical studies. Based on this progress, Sirtris has initiated a Phase 1b study in patients with Type 2 Diabetes.
